TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Mechanical Bowel Preparation in Pelvic Reconstructive Surgery (MBP)
Brief Summary: Does mechanical bowel preparation (complete bowel cleansing)help the Surgeon with visualization of the operative field during laparoscopic pelvic reconstructive surgery?


Options:
A: Arm Label: SSLF and PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF, Behavioral: PMT | Arm Label: ULS and PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS, Behavioral: PMT | Arm Label: SSLF without PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF | Arm Label: ULS without PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS | Intervention Type: PROCEDURE; Name: SSLF; Assigned to Arm(s): SSLF and PMT, SSLF without PMT | Intervention Type: PROCEDURE; Name: ULS; Assigned to Arm(s): ULS and PMT, ULS without PMT | Intervention Type: BEHAVIORAL; Name: PMT; Assigned to Arm(s): SSLF and PMT, ULS and PMT
B: Arm Label: IV Acetaminophen; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Acetaminophen | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen, Saline
C: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Mechanical Bowel Prep; Type: ACTIVE_COMPARATOR; Interventions: Other: Mechanical Bowel Prep | Arm Label: No Mechanical Bowel Prep.; Type: ACTIVE_COMPARATOR; Interventions: Other: No Mechanical Bowel Prep | Intervention Type: OTHER; Name: Mechanical Bowel Prep; Assigned to Arm(s): Mechanical Bowel Prep | Intervention Type: OTHER; Name: No Mechanical Bowel Prep; Assigned to Arm(s): No Mechanical Bowel Prep.

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation
Brief Summary: The primary objective of this study is to evaluate the effect of ranolazine and of low-dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment. AFB is defined as the total time a participant is in atrial tachycardia/atrial fibrillation (AT/AF) expressed as a percentage of total recording time.


Options:
A: Arm Label: AAD:YES; Type: OTHER; Interventions: Drug: propafenone; flecainide; sotalol; dofetilide, Device: Radiofrequency catheter ablation | Arm Label: AAD:NO; Type: OTHER; Interventions: Device: Radiofrequency catheter ablation | Intervention Type: DRUG; Name: propafenone; flecainide; sotalol; dofetilide; Assigned to Arm(s): AAD:YES | Intervention Type: DEVICE; Name: Radiofrequency catheter ablation; Assigned to Arm(s): AAD:NO, AAD:YES
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ranolazine placebo, Drug: Dronedarone placebo | Arm Label: Ranolazine 750 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Dronedarone placebo | Arm Label: Dronedarone 225 mg; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone, Drug: Ranolazine placebo | Arm Label: Ranolazine 750 mg + Dronedarone 225 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Dronedarone | Arm Label: Ranolazine 750 mg + Dronedarone 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Dronedarone | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine 750 mg, Ranolazine 750 mg + Dronedarone 150 mg, Ranolazine 750 mg + Dronedarone 225 mg | Intervention Type: DRUG; Name: Dronedarone; Assigned to Arm(s): Dronedarone 225 mg, Ranolazine 750 mg + Dronedarone 150 mg, Ranolazine 750 mg + Dronedarone 225 mg | Intervention Type: DRUG; Name: Ranolazine placebo; Assigned to Arm(s): Dronedarone 225 mg, Placebo | Intervention Type: DRUG; Name: Dronedarone placebo; Assigned to Arm(s): Placebo, Ranolazine 750 mg
C: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy
D: Arm Label: No Amiodarone; Type: ACTIVE_COMPARATOR; Interventions: Other: No Amiodarone | Arm Label: Amiodarone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: No Amiodarone; Assigned to Arm(s): No Amiodarone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility Study of Preoperative Exercise Intervention in the Resection of Colorectal Liver Metastasis.
Brief Summary: Each year in the UK around 1500 patients undergo surgery for bowel cancer that has spread to the liver. This is major surgery that offers a chance of cure, but can be associated with complications. Fitter patients are less likely to have serious complications. We are interested in finding out whether a short exercise program can improve patient fitness before surgery and whether this can reduce surgical complications.

We plan to measure the fitness of patients who are going to have liver surgery. We will then give them an exercise programme for 4 weeks, after which we will assess their fitness again.

We are also interested in whether fitter people have better Liver function. To assess this we will take a small sample of liver tissue during the operation for laboratory analysis of its function.

Hypothesis

1. A short period of exercise can significantly improve fitness prior to liver surgery
2. Greater Fitness is associated with better liver function.


Options:
A: Arm Label: Pre-surgery physiotherapy; Type: OTHER; Interventions: Other: Pre-surgery physiotherapy | Arm Label: Waiting-list; Type: OTHER; Interventions: Other: Waiting-list | Intervention Type: OTHER; Name: Pre-surgery physiotherapy; Assigned to Arm(s): Pre-surgery physiotherapy | Intervention Type: OTHER; Name: Waiting-list; Assigned to Arm(s): Waiting-list
B: Arm Label: Exercise Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Intervention | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention
C: Arm Label: HIT; Type: EXPERIMENTAL; Interventions: Procedure: HIT | Arm Label: MCT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: MCT | Intervention Type: PROCEDURE; Name: HIT; Assigned to Arm(s): HIT | Intervention Type: PROCEDURE; Name: MCT; Assigned to Arm(s): MCT
D: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise programme | Arm Label: No Exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise programme; Assigned to Arm(s): Exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility Study of Preoperative Exercise Intervention in the Resection of Colorectal Liver Metastasis.
Brief Summary: Each year in the UK around 1500 patients undergo surgery for bowel cancer that has spread to the liver. This is major surgery that offers a chance of cure, but can be associated with complications. Fitter patients are less likely to have serious complications. We are interested in finding out whether a short exercise program can improve patient fitness before surgery and whether this can reduce surgical complications.

We plan to measure the fitness of patients who are going to have liver surgery. We will then give them an exercise programme for 4 weeks, after which we will assess their fitness again.

We are also interested in whether fitter people have better Liver function. To assess this we will take a small sample of liver tissue during the operation for laboratory analysis of its function.

Hypothesis

1. A short period of exercise can significantly improve fitness prior to liver surgery
2. Greater Fitness is associated with better liver function.


Options:
A: Arm Label: Pre-surgery physiotherapy; Type: OTHER; Interventions: Other: Pre-surgery physiotherapy | Arm Label: Waiting-list; Type: OTHER; Interventions: Other: Waiting-list | Intervention Type: OTHER; Name: Pre-surgery physiotherapy; Assigned to Arm(s): Pre-surgery physiotherapy | Intervention Type: OTHER; Name: Waiting-list; Assigned to Arm(s): Waiting-list
B: Arm Label: Exercise Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Intervention | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention
C: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Standard nutrition counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Prehabilitation Plus; Type: ACTIVE_COMPARATOR; Interventions: Other: Prehabilitation Plus | Arm Label: Rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Prehabilitation Plus; Assigned to Arm(s): Prehabilitation Plus

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters
Brief Summary: The purpose of this study is to compare compact intermittent catheters with standard coated intermittent catheters with regard to quality of life, using the Intermittent Self-Catheterisation Quality of life Measure.


Options:
A: Arm Label: Single-use catheter; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-use catheter, Diagnostic Test: Urine culture | Arm Label: Reused catheter with 0.5% benzalkonium chloride; Type: EXPERIMENTAL; Interventions: Procedure: Reused catheter, Diagnostic Test: Urine culture | Arm Label: Reused catheter with soap and water; Type: EXPERIMENTAL; Interventions: Procedure: Reused catheter, Diagnostic Test: Urine culture | Intervention Type: PROCEDURE; Name: Single-use catheter; Assigned to Arm(s): Single-use catheter | Intervention Type: PROCEDURE; Name: Reused catheter; Assigned to Arm(s): Reused catheter with 0.5% benzalkonium chloride, Reused catheter with soap and water | Intervention Type: DIAGNOSTIC_TEST; Name: Urine culture; Assigned to Arm(s): Reused catheter with 0.5% benzalkonium chloride, Reused catheter with soap and water, Single-use catheter
B: Arm Label: Compact catheter; Type: EXPERIMENTAL; Interventions: Device: SpeediCath Compact | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard care | Intervention Type: DEVICE; Name: SpeediCath Compact; Assigned to Arm(s): Compact catheter | Intervention Type: DEVICE; Name: Standard care; Assigned to Arm(s): Standard Care
C: Arm Label: SpeediCath catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: SpeediCath | Arm Label: Test product; Type: EXPERIMENTAL; Interventions: Device: Test Catheter - SpeediCath Compact Male | Intervention Type: DEVICE; Name: Test Catheter - SpeediCath Compact Male; Assigned to Arm(s): Test product | Intervention Type: DEVICE; Name: SpeediCath; Assigned to Arm(s): SpeediCath catheter
D: Arm Label: 30 cm Intermittent Catheter; Type: EXPERIMENTAL; Interventions: Device: 30 cm Intermittent Catheter | Arm Label: 40 cm Intermittent Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: 40 cm Intermittent Catheter | Intervention Type: DEVICE; Name: 30 cm Intermittent Catheter; Assigned to Arm(s): 30 cm Intermittent Catheter | Intervention Type: DEVICE; Name: 40 cm Intermittent Catheter; Assigned to Arm(s): 40 cm Intermittent Catheter

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial Comparing Use of Rapid Molecular Testing for Staphylococcus Aureus for Patients With Cutaneous Abscesses in the Emergency Department With Standard of Care.
Brief Summary: This study expands upon pilot data for feasibility since May 2011. The study aims to evaluate the effect of rapid test availability on use of targeted spectrum antibiotics for non-MRSA abscesses in ambulatory patients in the Emergency Department (ED). The multi-institutional study will assess the feasibility of providing the GeneXpert® MRSA/SA SSTI assay to the ED and evaluate the impact of delivering the test result to clinicians in real-time on patient management decisions regarding the use of antimicrobial agents. Patients are randomized to standard culture (control arm) or to the GeneXpert® assay plus standard culture.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: detection of microbial DNA in blood by blood culture | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Detection of microbial DNA in blood by SeptiFast® | Intervention Type: OTHER; Name: Detection of microbial DNA in blood by SeptiFast®; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: detection of microbial DNA in blood by blood culture; Assigned to Arm(s): 2
B: Arm Label: Control; Type: EXPERIMENTAL; Interventions: Other: Bacterial culture, Other: Susceptibility testing | Arm Label: FilmArray test; Type: EXPERIMENTAL; Interventions: Device: FilmArray testing, Other: Bacterial culture, Other: Susceptibility testing | Arm Label: FilmArray plus antimicrobial stewardship; Type: EXPERIMENTAL; Interventions: Device: FilmArray testing, Behavioral: Antimicrobial Stewardship, Other: Bacterial culture, Other: Susceptibility testing | Intervention Type: DEVICE; Name: FilmArray testing; Assigned to Arm(s): FilmArray plus antimicrobial stewardship, FilmArray test | Intervention Type: BEHAVIORAL; Name: Antimicrobial Stewardship; Assigned to Arm(s): FilmArray plus antimicrobial stewardship | Intervention Type: OTHER; Name: Bacterial culture; Assigned to Arm(s): Control, FilmArray plus antimicrobial stewardship, FilmArray test | Intervention Type: OTHER; Name: Susceptibility testing; Assigned to Arm(s): Control, FilmArray plus antimicrobial stewardship, FilmArray test
C: Arm Label: Pathogen detection by Multiplex PCR; Type: ACTIVE_COMPARATOR; Interventions: Other: Antibiotic regimen | Arm Label: Pathogen detection by blood culture; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Antibiotic regimen; Assigned to Arm(s): Pathogen detection by Multiplex PCR
D: Arm Label: Xpert MRSA/SA SSTI; Type: EXPERIMENTAL; Interventions: Device: Xpert MRSA/SA SSTI | Arm Label: Standard culture; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Standard culture | Intervention Type: DEVICE; Name: Xpert MRSA/SA SSTI; Assigned to Arm(s): Xpert MRSA/SA SSTI | Intervention Type: DIAGNOSTIC_TEST; Name: Standard culture; Assigned to Arm(s): Standard culture

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The RITA-study -- An Open Study to Evaluate the Blood Lipid Lowering Effect of Rosuvastatin Versus Fluvastatin and the Bilateral Interaction Between Everolimus and Rosuvastatin in Renal Transplant Recipients
Brief Summary: Renal transplant recipients need life long immunosuppression and one of the new drugs is everolimus. Everolimus is a potent immunosuppressive drug and one of the main side-effects are increased blood cholesterol levels. Many renal transplant recipients are treated with a cholesterol lowering agent, mainly fluvastatin. Rosuvastatin is a new cholesterol lowering drug on the market with a potential higher cholesterol lowering potency. In the present study the investigators will examine the hypothesis that rosuvastatin reduce cholesterol levels more than fluvastatin in renal transplant patients.


Options:
A: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
B: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
D: Arm Label: Fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluvastatin | Arm Label: Fluvastatin + Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin plus ezetimibe | Intervention Type: DRUG; Name: fluvastatin; Assigned to Arm(s): Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin plus ezetimibe; Assigned to Arm(s): Fluvastatin + Ezetimibe

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin
Brief Summary: The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of carcinoid syndrome.


Options:
A: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Other: Best suportive care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best suportive care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: OTHER; Name: Best suportive care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
B: Arm Label: 177Lu-DOTA0-Tyr3-Octreotate; Type: EXPERIMENTAL; Interventions: Drug: Octreotide LAR, Drug: 177Lu-DOTA0-Tyr3-Octreotate | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide LAR | Intervention Type: DRUG; Name: Octreotide LAR; Assigned to Arm(s): 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR | Intervention Type: DRUG; Name: 177Lu-DOTA0-Tyr3-Octreotate; Assigned to Arm(s): 177Lu-DOTA0-Tyr3-Octreotate
C: Arm Label: Lanreotide Autogel (Somatuline Depot) 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide | Arm Label: Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanreotide; Assigned to Arm(s): Lanreotide Autogel (Somatuline Depot) 120 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE
D: Arm Label: lanreotide; Type: EXPERIMENTAL; Interventions: Drug: lanreotide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide; Assigned to Arm(s): lanreotide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects
Brief Summary: The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine lipoarabinomannan (LAM) test in detecting tuberculosis in HIV-infected adults.

A secondary study objective is to determine the accuracy, efficiency, costs, and cost-effectiveness of various combinations of Tuberculosis (TB) diagnostic tests, including the novel Xpert MTB/Rif test.


Options:
A: N/A
B: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A
C: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
D: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects
Brief Summary: The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine lipoarabinomannan (LAM) test in detecting tuberculosis in HIV-infected adults.

A secondary study objective is to determine the accuracy, efficiency, costs, and cost-effectiveness of various combinations of Tuberculosis (TB) diagnostic tests, including the novel Xpert MTB/Rif test.


Options:
A: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
B: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A
C: Arm Label: Novel; Type: EXPERIMENTAL; Interventions: Procedure: GeneXpert MTB/RIF assay, Procedure: Smear microscopy | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: GeneXpert MTB/RIF assay; Assigned to Arm(s): Novel | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Novel, Standard
D: Arm Label: Urgent ART; Type: EXPERIMENTAL; Interventions: Other: Urgent ART | Arm Label: Early ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Early ART | Intervention Type: OTHER; Name: Urgent ART; Assigned to Arm(s): Urgent ART | Intervention Type: OTHER; Name: Early ART; Assigned to Arm(s): Early ART

Answer: B